PROJECT TITLE

AutoRECIST – software to assist a radiologist in assessing the effectiveness of oncological treatment for female patients with breast cancer tumours metastatic to the lungs, liver, brain and lymph nodes in the RECIST system.

CO-FUNDING

The project is co-financed from the state budget and European Union funds. The funds come from the National Recovery and Resilience Plan (KPO) and the European Union’s NextGenerationEU (NGEU) financial instrument.

Graylight Imaging Spółka z ograniczoną odpowiedzialnością:

  • the maximum funding for industrial research is PLN 1,415,982.02, representing 80.00% of the entity’s expenditure on industrial research.
  • the maximum funding for development work is PLN 1,907,727.70, representing 60% of the entity’s expenditure on development work.

National Institute of Oncology – Maria Skłodowska-Curie Memorial – State Research Institute in Gliwice:

  • the maximum funding for industrial research is PLN 413,088.00, representing 100.00% of the entity’s expenditure on industrial research
  • the maximum amount of funding for development work is PLN 143,712.00, which represents 100.00% of the amount of expenditure on development work incurred by the entity

 Co-funding was granted under an agreement signed on 24 April 2025.

PROJECT DESCRIPTION

The aim of the project is to develop software to assist radiologists in assessing the effectiveness of cancer treatment using the RECIST (Response Evaluation Criteria in Solid Tumours) system.

The RECIST criteria were developed to standardise the assessment of tumour response to treatment. The strict rules in RECIST are intended to enable comparison of treatment outcomes across different centres, treatment modalities, and clinical trials. The main disadvantage of RECIST is its strong reliance on radiologists’ descriptions of the examination. Such an assessment is subjective, not always accurate, prone to human error, non-reproducible, and inconsistent with RECIST; it must be corrected by a radiologist to meet RECIST criteria. The creation of an automatic RECIST assessment system will enable its objectification and significant acceleration. Its application in clinical practice will increase the accuracy and speed of oncology diagnostics at an acceptable market cost.

The research and development work carried out within the project focuses on selecting appropriate scans, preparation of manual tumour outlines on scans, creation and verification of artificial intelligence algorithms for tumour detection, segmentation and analysis, preparation of a user interface enabling work with the results, and validation of the algorithms and interface in real conditions (clinical environment).

The implementation of the Project and the introduction of the Medical Device into clinical practice will positively influence radiologists’ work and the quality of their RECIST-based evaluation of oncological treatment effectiveness by standardising it and significantly accelerating its use.